Anemia drug by Takeda and Affymax is submitted for FDA OK

05/31/2011 | Forbes · Pharmaceutical Business Review Online

Affymax and Takeda Pharmaceutical are seeking FDA approval of peginesatide, a drug candidate for anemia in kidney dialysis patients. The once-monthly drug, formerly called Hematide, appears as safe and effective as epoetin alfa or epoetin beta in stabilizing hemoglobin level, according to results of two Phase III trials.

View Full Article in:

Forbes · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY